Two Sigma Advisers
SYRS

Two Sigma Advisers’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Two Sigma Advisers’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,550
Closed -$61.8K – 2717
2024
Q1 		$61.8K Buy
+11,550
New +$79.9K ﹤0.01% 2338
2022
Q2 		– Sell
-10,670
Closed -$127K – 2924
2022
Q1 		$127K Buy
10,670
+1,610
+18% +$28.8K ﹤0.01% 2470
2021
Q4 		$295K Sell
9,060
-8,210
-48% -$332K ﹤0.01% 2148
2021
Q3 		$772K Sell
17,270
-8,340
-33% -$407K ﹤0.01% 1734
2021
Q2 		$1.4M Sell
25,610
-3,970
-13% -$235K ﹤0.01% 1481
2021
Q1 		$2.21M Buy
29,580
+6,500
+28% +$675K 0.01% 1217
2020
Q4 		$2.5M Buy
23,080
+4,870
+27% +$444K 0.01% 1140
2020
Q3 		$1.61M Sell
18,210
-20
-0.1% -$2.27K ﹤0.01% 1275
2020
Q2 		$1.94M Buy
18,230
+10,190
+127% +$915K 0.01% 1215
2020
Q1 		$477K Sell
8,040
-2,510
-24% -$170K ﹤0.01% 1832
2019
Q4 		$729K Buy
+10,550
New +$640K ﹤0.01% 1709
2019
Q3 		– Sell
-3,800
Closed -$352K – 2425
2019
Q2 		$352K Sell
3,800
-300
-7% -$20.9K ﹤0.01% 1949
2019
Q1 		$375K Sell
4,100
-980
-19% -$68.3K ﹤0.01% 1906
2018
Q4 		$283K Sell
5,080
-460
-8% -$35K ﹤0.01% 2013
2018
Q3 		$660K Sell
5,540
-1,860
-25% -$216K ﹤0.01% 1686
2018
Q2 		$756K Buy
+7,400
New +$916K ﹤0.01% 1735
2018
Q1 		– Sell
-1,080
Closed -$105K – 2446
2017
Q4 		$105K Buy
+1,080
New +$145K ﹤0.01% 2145

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Two Sigma Advisers's SYRS Position: Q2 2024 in Review

Two Sigma Advisers sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 11,550 shares — an estimated $61.8K sold.

Two Sigma Advisers first reported a position in SYRS in Q4 2017 and held it in 17 quarters. The position peaked at $2.5M in Q4 2020. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

  • Two Sigma Advisers reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 11,550 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $61.8K.
  • Two Sigma Advisers first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Two Sigma Advisers's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.5M in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.